Hepatocellular Carcinoma disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

HCC MCID: HPT023 MIFTS: 96	Hepatocellular Carcinoma (HCC) Categories: Cancer diseases, Gastrointestinal diseases, Genetic diseases, Liver diseases, Rare diseases	Data Licensing For inquiries, contact: [email protected]
Genes Variations Tissues Related diseases Publications Symptoms & Phenotypes Drugs Expand all tables

Sources

Aliases & Classifications for Hepatocellular Carcinoma

MalaCards integrated aliases for Hepatocellular Carcinoma:

Name: Hepatocellular Carcinoma ⁵⁷ ¹¹ ⁵⁸ ⁷⁵ ⁷³ ²⁸ ⁵³ ⁵ ¹⁴ ³⁶ ¹⁶

Liver Cancer ⁵⁷ ¹¹ ⁷³ ⁴¹ ¹⁴ ³³

Primary Liver Cancer ¹¹ ¹⁹ ¹⁴ ³³

Malignant Neoplasm of Liver ¹¹ ⁷¹ ³³

Liver Neoplasms ⁷⁵ ⁴³ ⁷¹

Hepatoma ⁵⁷ ¹¹ ⁷³

Hcc ⁵⁷ ⁵⁸ ⁷³

Rare Tumor of Liver and Intrahepatic Biliary Tract ¹⁹ ⁵⁸

Primary Malignant Neoplasm of Liver ¹¹ ⁷¹

Hepatoblastoma, Somatic ⁵⁷ ¹²

Cancer, Hepatocellular ⁵⁷ ³⁸

Liver Cell Carcinoma ⁵⁷ ⁷³

Hepatic Cancer ¹¹ ⁵³

Lcc ⁵⁷ ⁷³

Malignant Neoplasm of Liver, Not Specified As Primary or Secondary ¹¹

Hepatocellular Carcinoma, Childhood Type, Somatic ⁵⁷

Non-Resectable Primary Hepatic Malignant Neoplasm ¹¹

Liver and Intrahepatic Biliary Tract Carcinoma ⁷¹

Resectable Malignant Neoplasm of the Liver ¹¹

Adult Primary Hepatocellular Carcinoma ⁷¹

Resectable Malignant Neoplasm of Liver ¹¹

Malignant Neoplasm of Liver, Primary ¹¹

Hepatocellular Carcinoma, Somatic ⁵⁷

Malignant Hepato-Biliary Neoplasm ¹¹

Primary Malignant Liver Neoplasm ¹⁹

Malignant Hepatobiliary Neoplasm ⁷¹

Hepatocellular Cancer, Somatic ⁵⁷

Rare Tumor of Liver and Ibt ⁵⁸

Primary Tumor of the Liver ¹⁹

Carcinoma, Hepatocellular ⁴³

Malignant Tumor of Liver ¹¹

Malignant Hepatic Tumour ³³

Primary Liver Carcinoma ¹⁹

Primary Cancer of Liver ¹⁹

Malignant Liver Tumour ³³

Hepatocellular Cancer ⁷³

Neoplasm of the Liver ⁵

Ca Liver - Primary ¹¹

Carcinoma of Liver ³³

Neoplasm of Liver ¹¹

Hepatic Neoplasm ¹¹

Liver Carcinoma ⁷¹

Hepatoblastoma ⁷¹

Liver Neoplasm ¹⁶

Hepatomas ¹⁴

Characteristics:

Inheritance:

Somatic mutation ⁵⁷

Prevelance:

1-9/100000 (United States, France, United Kingdom, Germany, Spain, Italy, Canada, Oceania, Europe, Austria, Belgium, Bulgaria, Croatia, Czech Republic, Estonia, Finland, Iceland, Ireland, Latvia, Lithuania, Norway, Portugal, Slovakia, Switzerland, Netherlands) 1-5/10000 (Europe, Greece, Latin America, China, Japan, Korea, Republic of, Africa) 6-9/10000 (Mongolia) 1-9/1000000 (Poland) ⁵⁸

Age Of Onset:

All ages ⁵⁸

OMIM®:

⁵⁷ (Updated 08-Dec-2022)

Miscellaneous:
genetic heterogeneity

Classifications:

MalaCards categories:
Global: Genetic diseases Rare diseases Cancer diseases
Anatomical: Liver diseases Gastrointestinal diseases

See all MalaCards categories (disease lists)

ICD10: ³¹ ³²

Neoplasms

Malignant neoplasms of digestive organs

Malignant neoplasm of liver and intrahepatic bile ducts

Malignant neoplasm: Liver cell carcinoma

Malignant neoplasm: Liver, unspecified

ICD11: ³³

Neoplasms

Malignant neoplasms, except primary neoplasms of lymphoid, haematopoietic, central nervous system or related tissues

Malignant neoplasms, stated or presumed to be primary, of specified sites, except of lymphoid, haematopoietic, central nervous system or related tissues

Malignant neoplasms of digestive organs

Malignant neoplasms of liver or intrahepatic bile ducts

Malignant neoplasm of liver

Other specified malignant neoplasm of liver

Orphanet: ⁵⁸

Rare hepatic diseases

External Ids:

Disease Ontology ¹¹ DOID:3571 DOID:684

OMIM® ⁵⁷ 114550

ICD9CM ³⁴ 155.0 155.2

MeSH ⁴³ D006528 D008113

NCIt ⁴⁹ C3099 C34803 C7692

SNOMED-CT ⁶⁸ 126851005 154469006 187771009 more

ICD10 ³¹ C22.0 C22.9

MESH via Orphanet ⁴⁴ D006528

ICD10 via Orphanet ³² C22.0

UMLS via Orphanet ⁷² C0023903 C2239176

Orphanet ⁵⁸ ORPHA306636 ORPHA88673

MedGen ⁴⁰ C0206624 C0345904 C2239176 more

EFO ¹⁶ EFO_0000182 EFO_1001513

ICD11 ³³ 1605020868 1605020868/other

UMLS ⁷¹ C0023903 C0024620 C0206624 more

Sources

Summaries for Hepatocellular Carcinoma

MedlinePlus: ⁴¹ Your liver is the largest organ inside your body. It helps your body digest food, store energy, and remove poisons. Primary liver cancer starts in the liver. Metastatic liver cancer starts somewhere else and spreads to your liver. Risk factors for primary liver cancer include : Having hepatitis B or C Heavy alcohol use Having cirrhosis, or scarring of the liver Having hemochromatosis, an iron storage disease Obesity and diabetes Symptoms can include a lump or pain on the right side of your abdomen and yellowing of the skin. However, you may not have symptoms until the cancer is advanced. This makes it harder to treat. Doctors use tests that examine the liver and the blood to diagnose liver cancer. Treatment options include surgery, radiation, chemotherapy, or liver transplantation. NIH: National Cancer Institute

MalaCards based summary: Hepatocellular Carcinoma, also known as liver cancer, is related to colorectal cancer and adult hepatocellular carcinoma, and has symptoms including nausea and vomiting, constipation and fever. An important gene associated with Hepatocellular Carcinoma is PIK3CA (Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha), and among its related pathways/superpathways are Alzheimer's disease and miRNA effects and ncRNAs involved in Wnt signaling in hepatocellular carcinoma. The drugs Sargramostim and Lenograstim have been mentioned in the context of this disorder. Affiliated tissues include liver, t cells and bone marrow, and related phenotypes are hepatomegaly and portal hypertension

OMIM®: ⁵⁷ Hepatocellular carcinoma is the major histologic type of malignant primary liver neoplasm. It is the fifth most common cancer and the third most common cause of death from cancer worldwide. The major risk factors for HCC are chronic hepatitis B virus (HBV) infection, chronic hepatitis C virus (HCV) infection, prolonged dietary aflatoxin exposure, alcoholic cirrhosis, and cirrhosis due to other causes. Hepatoblastomas comprise 1 to 2% of all malignant neoplasms of childhood, most often occurring in children under 3 years of age. Hepatoblastomas are thought to be derived from undifferentiated hepatocytes (Taniguchi et al., 2002). (114550) (Updated 08-Dec-2022)

GARD: ¹⁹ A rare carcinoma of the liver characterized by one to several or many nodules occurring anywhere within the liver, composed of neoplastic epithelial cells with hepatocellular differentiation. The vast majority of tumors are associated with chronic liver disease (such as hepatitis B or C, or steatohepatitis) or exposure to a variety of exogenous agents. Patients may present with signs and symptoms related to the tumor, as well as to the underlying condition. Common manifestations include right upper quadrant abdominal pain, weight loss, hepatosplenomegaly, jaundice, and ascites. Symptomatic tumors generally have poor prognosis.

UniProtKB/Swiss-Prot: ⁷³ A primary malignant neoplasm of epithelial liver cells. The major risk factors for HCC are chronic hepatitis B virus (HBV) infection, chronic hepatitis C virus (HCV) infection, prolonged dietary aflatoxin exposure, alcoholic cirrhosis, and cirrhosis due to other causes.

Orphanet: ⁵⁸ Hepatocellular carcinoma is a primary hepatic cancer derived from well-differentiated hepatocytes. It is more frequent in adults than in childhood. Symptoms are hepatic mass, abdominal pain and, in advanced stages, jaundice, cachexia and liver failure.

Disease Ontology ¹¹ Hepatocellular carcinoma: A liver carcinoma that has material basis in undifferentiated hepatocytes and located in the liver.

Liver cancer: A hepatobiliary system cancer that is located in the liver.

Wikipedia: ⁷⁵ Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer in adults and is... more...

Sources

Related Diseases for Hepatocellular Carcinoma

Diseases in the Hepatocellular Carcinoma family:

Adult Hepatocellular Carcinoma

Diseases related to Hepatocellular Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 2025)

#	Related Disease	Score	Top Affiliating Genes
1	colorectal cancer	34.3	TP53 TERT PIK3CA PDGFRL MIR34A MIR224
2	adult hepatocellular carcinoma	34.2	TP53 PIK3CA PDGFRL CTNNB1 CASP8 AXIN1
3	breast cancer	34.1	TP53 TERT PIK3CA MIR34A MIR221 MIR21
4	lung cancer	33.9	TP53 TERT PIK3CA MIR34A MIR224 MIR221
5	esophageal cancer	33.8	TP53 TERT PIK3CA MIR34A MIR221 MIR21
6	type 2 diabetes mellitus	33.7	TP53 TERT PIK3CA MIR34A MIR224 MIR221
7	cholangiocarcinoma	33.7	TP53 TERT PIK3CA MIR21 MIR200B MET
8	gastric cancer	33.6	TP53 TERT PIK3CA MIR34A MIR221 MIR21
9	pancreatic cancer	33.6	TP53 TERT PIK3CA MIR34A MIR221 MIR21
10	non-alcoholic fatty liver disease	33.6	MIR34A MIR21 MIR200B MIR17 MIR122 ALB
11	prostate cancer	33.6	TP53 TERT PIK3CA MIR34A MIR224 MIR221
12	liver disease	33.6	MIR34A MIR21 MIR155 MIR122 ALB
13	hepatitis b	33.6	PIK3CA MIR21 MIR17 ALB
14	renal cell carcinoma, nonpapillary	33.5	TP53 PIK3CA MIR34A MIR224 MIR221 MIR21
15	melanoma	33.4	TP53 TERT PIK3CA MIR34A MIR224 MIR221
16	ovarian cancer	33.4	TP53 TERT PIK3CA MIR34A MIR221 MIR21
17	fatty liver disease	33.2	MIR34A MIR21 MIR155 MIR122
18	leukemia, acute myeloid	33.2	TP53 TERT PIK3CA MIR34A MIR221 MIR21
19	diabetes mellitus	33.2	TP53 MIR34A MIR21 MIR17 MIR155 MIR122
20	hemochromatosis, type 1	33.2	MIR34A MIR122 AXIN1 ALB
21	brain cancer	33.1	TP53 TERT PIK3CA MIR34A MIR224 MIR221
22	bile duct cancer	33.1	TP53 PIK3CA MIR221 MIR21 MIR17 MET
23	non-alcoholic steatohepatitis	33.1	MIR34A MIR21 MIR122 ALB
24	lung cancer susceptibility 3	33.1	TP53 TERT PIK3CA MIR21 MIR200B MIR17
25	body mass index quantitative trait locus 11	33.1	TP53 MIR34A MIR221 MIR21 MIR18A MIR17
26	lymphoma, non-hodgkin, familial	33.1	TP53 PIK3CA MIR34A MIR224 MIR21 MIR200B
27	glioblastoma	33.0	TP53 TERT PIK3CA MIR34A MIR221 MIR21
28	hypertension, essential	32.9	TP53 MIR34A MIR221 MIR21 MIR17 MIR155
29	squamous cell carcinoma, head and neck	32.8	TP53 PIK3CA MIR221 MIR21 MIR200B MIR18A
30	intrahepatic cholangiocarcinoma	32.8	TP53 MIR17 CTNNB1 ALB
31	hepatoblastoma	32.8	TP53 TERT MET CTNNB1 APC
32	hematologic cancer	32.8	MIR34A MIR221 MIR21 MIR200B MIR18A MIR17
33	medulloblastoma	32.7	TP53 TERT PIK3CA MIR34A MIR221 MIR18A
34	neuroblastoma	32.7	TP53 TERT PIK3CA MIR34A MIR221 MIR21
35	endometrial cancer	32.7	TP53 TERT PIK3CA MIR21 MIR200B MET
36	adenocarcinoma	32.7	TP53 PIK3CA MET CTNNB1 APC
37	adenoma	32.7	TP53 PIK3CA CTNNB1 APC
38	cervical cancer	32.7	TP53 TERT PIK3CA MIR34A MIR224 MIR221
39	gastrointestinal system disease	32.7	MIR34A MIR224 MIR221 MIR21 MIR200B MIR18A
40	colonic benign neoplasm	32.7	TP53 PIK3CA MIR21 MIR18A CTNNB1 AXIN1
41	bladder cancer	32.7	TP53 TERT PIK3CA MIR221 MIR21 MIR17
42	head and neck cancer	32.6	TP53 PIK3CA MIR34A MIR224 MIR221 MIR21
43	leukemia, chronic lymphocytic	32.6	TP53 MIR34A MIR224 MIR221 MIR21 MIR200B
44	nasopharyngeal carcinoma	32.6	TP53 TERT PIK3CA MIR21 MIR18A MIR17
45	peripheral nervous system disease	32.6	TP53 TERT MIR34A MIR21 MIR200B MIR17
46	skin disease	32.6	TP53 TERT PIK3CA MIR34A MIR224 MIR221
47	lymphatic system disease	32.5	TP53 MIR34A MIR224 MIR221 MIR21 MIR200B
48	kidney cancer	32.5	TP53 PIK3CA MIR21 MIR200B MIR17 MIR122
49	gallbladder cancer	32.5	TP53 TERT PIK3CA MIR17 CTNNB1 APC
50	immune deficiency disease	32.4	MIR34A MIR221 MIR21 MIR17 MIR155 MIR122

Comorbidity relations with Hepatocellular Carcinoma via Phenotypic Disease Network (PDN):

Active Peptic Ulcer Disease	Acute Cystitis
Alcoholic Liver Cirrhosis	Deficiency Anemia
Hepatic Encephalopathy	Intrahepatic Gall Duct Cancer
Portal Hypertension	Protein-Energy Malnutrition

Graphical network of the top 20 diseases related to Hepatocellular Carcinoma:

Sources

Symptoms & Phenotypes for Hepatocellular Carcinoma

Human phenotypes related to Hepatocellular Carcinoma:

⁵⁸ ³⁰ (show top 50) (show all 51)

#	Description	HPO Frequency	Orphanet Frequency	HPO Source Accession
1	hepatomegaly ⁵⁸ ³⁰	Hallmark (90%)	Very frequent (99-80%)	HP:0002240
2	portal hypertension ⁵⁸ ³⁰	Hallmark (90%)	Very frequent (99-80%)	HP:0001409
3	abdominal pain ⁵⁸ ³⁰	Hallmark (90%)	Very frequent (99-80%)	HP:0002027
4	hyperbilirubinemia ⁵⁸ ³⁰	Hallmark (90%)	Very frequent (99-80%)	HP:0002904
5	hypoalbuminemia ⁵⁸ ³⁰	Hallmark (90%)	Very frequent (99-80%)	HP:0003073
6	type ii diabetes mellitus ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0005978
7	elevated hepatic transaminase ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0002910
8	anorexia ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0002039
9	weight loss ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0001824
10	esophageal varix ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0002040
11	venous insufficiency ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0005293
12	abdominal distention ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0003270
13	epigastric pain ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0410019
14	abnormal rectum morphology ³⁰	Frequent (33%)		HP:0002034
15	hypokalemia ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0002900
16	fatigue ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0012378
17	fever ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0001945
18	hypoglycemia ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0001943
19	anemia ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0001903
20	ascites ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0001541
21	thrombocytopenia ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0001873
22	jaundice ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0000952
23	dyspnea ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0002094
24	neoplasm ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0002664
25	hyponatremia ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0002902
26	hypercalcemia ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0003072
27	internal hemorrhage ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0011029
28	polycythemia ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0001901
29	bone pain ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0002653
30	poor appetite ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0004396
31	diarrhea ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0002014
32	pedal edema ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0010741
33	hepatic encephalopathy ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0002480
34	thrombocytosis ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0001894
35	metabolic alkalosis ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0200114
36	hepatic necrosis ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0002605
37	anasarca ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0012050
38	hemobilia ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0100762
39	emotional lability ³⁰	Occasional (7.5%)		HP:0000712
40	hypotension ⁵⁸ ³⁰	Very rare (1%)	Very rare (<4-1%)	HP:0002615
41	liver abscess ⁵⁸ ³⁰	Very rare (1%)	Very rare (<4-1%)	HP:0100523
42	budd-chiari syndrome ⁵⁸ ³⁰	Very rare (1%)	Very rare (<4-1%)	HP:0002639
43	abnormality of the liver ⁵⁸		Very frequent (99-80%)
44	hepatocellular carcinoma ³⁰			HP:0001402
45	abnormality of the hepatic vasculature ⁵⁸		Very frequent (99-80%)
46	abnormality of the rectum ⁵⁸		Frequent (79-30%)
47	mood changes ⁵⁸		Occasional (29-5%)
48	abnormality of glycoprotein metabolism ⁵⁸		Occasional (29-5%)
49	constitutional symptom ⁵⁸		Occasional (29-5%)
50	micronodular cirrhosis ³⁰			HP:0001413

Symptoms via clinical synopsis from OMIM®:

⁵⁷ (Updated 08-Dec-2022)

Abdomen Liver:
hepatocellular carcinoma
micronodular cirrhosis
subacute progressive viral hepatitis

Laboratory Abnormalities:
often integrated hbv sequences in hepatocellular carcinomas

Neoplasia:
primary liver cancer

Clinical features from OMIM®:

114550 (Updated 08-Dec-2022)

UMLS symptoms related to Hepatocellular Carcinoma:

nausea and vomiting; constipation; fever; abdominal pain; diarrhea; hepatosplenomegaly; dyspepsia; icterus; heartburn; gastrointestinal gas; malaise

MGI Mouse Phenotypes related to Hepatocellular Carcinoma:

⁴⁵

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	normal	MP:0002873	10.14	ALB APC AXIN1 CTNNB1 IGF2R MET
2	neoplasm	MP:0002006	10.13	ALB APC CASP8 CTNNB1 MET MIR122
3	endocrine/exocrine gland	MP:0005379	10.03	ALB APC CASP8 CTNNB1 IGF2R MET
4	renal/urinary system	MP:0005367	10.02	ALB APC AXIN1 CASP8 CTNNB1 IGF2R
5	liver/biliary system	MP:0005370	9.97	ALB APC CASP8 CTNNB1 IGF2R MET
6	digestive/alimentary	MP:0005381	9.81	ALB APC AXIN1 CTNNB1 MET MIR155
7	cellular	MP:0005384	9.73	ALB APC AXIN1 CASP8 CTNNB1 IGF2R
8	respiratory system	MP:0005388	9.28	AXIN1 CASP8 CTNNB1 IGF2R MET MIR155

Sources

Drugs & Therapeutics for Hepatocellular Carcinoma

Drugs for Hepatocellular Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 637)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Sargramostim

Approved, Investigational

Phase 4

123774-72-1

Lenograstim

Approved, Investigational

Phase 4

135968-09-1

Pregabalin

Approved, Investigational

Phase 4

148553-50-8

5486971

Propranolol

Approved, Investigational

Phase 4

318-98-9, 525-66-6

62882 4946

Cefazolin

Approved

Phase 4

25953-19-9

33255

Acetic acid

Approved

Phase 4

64-19-7

176

Nadolol

Approved

Phase 4

42200-33-9

39147

Triamcinolone

Approved, Vet_approved

Phase 4

124-94-7

31307

Iodine

Approved, Investigational

Phase 4

7553-56-2

807

Rocuronium

Approved

Phase 4

119302-91-9, 143558-00-3

441290

Velpatasvir

Approved, Investigational

Phase 4

1377049-84-7

77335690 67683363

Celecoxib

Approved, Investigational

Phase 4

169590-42-5

2662

Difluocortolone

Approved, Investigational, Withdrawn

Phase 4

2607-06-9

14445457 11954369

Norepinephrine

Approved

Phase 4

51-41-2

439260

Nicotine

Approved

Phase 4

54-11-5

942 89594

Bupropion

Approved

Phase 4

31677-93-7, 34841-39-9, 34911-55-2

444

Dexmedetomidine

Approved, Experimental, Vet_approved

Phase 4

86347-14-0, 113775-47-6

68602 5311068

Atropine

Approved, Vet_approved

Phase 4

101-31-5, 5908-99-6, 51-55-8

3661 154417 174174

Chlorhexidine

Approved, Vet_approved, Withdrawn

Phase 4

55-56-1

2713 9552079

Povidone-iodine

Approved

Phase 4

25655-41-8

Povidone K30

Approved, Experimental, Withdrawn

Phase 4

9003-39-8

6917 131751496

Edetate calcium disodium anhydrous

Approved, Vet_approved

Phase 4

62-33-9, 60-00-4

6049

Pentetic acid

Approved

Phase 4

67-43-6

Iron

Approved

Phase 4

7439-89-6

29936

Sevoflurane

Approved, Vet_approved

Phase 4

28523-86-6

5206

Propofol

Approved, Investigational, Vet_approved

Phase 4

2078-54-8

4943

Reviparin

Approved, Investigational

Phase 4

9041-08-1

Nitric Oxide

Approved

Phase 4

10102-43-9

145068

Fentanyl

Approved, Illicit, Investigational, Vet_approved

Phase 4

437-38-7

3345

Droperidol

Approved, Vet_approved

Phase 4

548-73-2

3168

Entecavir

Approved, Investigational

Phase 4

142217-69-4

153941

Azathioprine

Approved

Phase 4

446-86-6

2265

Lenvatinib

Approved, Investigational

Phase 4

417716-92-8

9823820

Coal tar

Approved

Phase 4

8007-45-2

Esketamine

Approved, Investigational

Phase 4

33643-46-8

182137

Meperidine

Approved

Phase 4

57-42-1

4058

Ondansetron

Approved, Withdrawn

Phase 4

99614-02-5

4595

Sufentanil

Approved, Investigational

Phase 4

56030-54-7

41693

Molgramostim

Investigational

Phase 4

99283-10-0

Thymalfasin

Investigational

Phase 4

62304-98-7

16167214 16130571

Zuretinol acetate

Investigational

Phase 4

127-47-9, 29584-22-3

10245972

Cadexomer iodine

Experimental

Phase 4

94820-09-4

Adefovir

Investigational

Phase 4

106941-25-7

Clevudine

Investigational

Phase 4

163252-36-6

Tenofovir

Experimental, Investigational

Phase 4

147127-20-6, 202138-50-9

464205 6398764

Immunologic Factors

Phase 4

Vasodilator Agents

Phase 4

Adjuvants, Immunologic

Phase 4

Fibrin Tissue Adhesive

Phase 4

Anti-Anxiety Agents

Phase 4

Interventional clinical trials:

(show top 50) (show all 3357)

#	Name	Status	NCT ID	Phase	Drugs
1	Chemoembolization With or Without Antiviral Therapy for Unresectable HBV-related Hepatocellular Carcinoma With Low HBV DNA Replication: Effectiveness and Safety. A Prospective and Randomized Clinical Trial	Unknown status	NCT01894269	Phase 4	Lamivudine 100mg once daily; or Entecavir 0.5mg once daily.
2	A Phase 4, Open-Label Study to Investigate the Efficacy and Safety of Tenofovir Disoproxil Fumarate (Viread(R)) in Preventing Hepatocellular Carcinoma Recurrence in Chronic Hepatitis B Virus Infected Patients With Low Viral Load at Baseline Treated With Radiofrequency Ablation or Resection	Unknown status	NCT02308319	Phase 4	Tenofovir disoproxil fumarate
3	Post-hepatectomy Adjuvant Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma Patients With Preoperative CTC Level ≥2: a Multicenter Randomized Controlled Trial in China	Unknown status	NCT02631499	Phase 4	Epirubicin;lipiodol
4	Efficacy of Antiviral Therapy With Lamivudine or Entecavir After Radical Resection for Hepatitis B Virus-Related Hepatocellular Carcinoma	Unknown status	NCT00768157	Phase 4	antiviral treatment (lamivudine or entecavir)
5	Nucleoid as an Adjuvant Therapy After Radiofrequency Ablation for Hepatocellular Carcinoma	Unknown status	NCT00555334	Phase 4	lamivudine or entecavir
6	Transcatheter Arterial Chemoembolization as an Adjuvant Therapy After Radiofrequency Ablation for Hepatocellular Carcinoma	Unknown status	NCT00556803	Phase 4
7	The Response and Outcomes of Pegylated Interferon Plus Ribavirin Combination Therapy for Chronic Hepatitis C Patients Concomitant With Hepatocellular Carcinoma	Unknown status	NCT00834860	Phase 4	peginterferon alpha-2a and ribavirin
8	A Prospective Randomized Control Study of Cidan Capsule Combined With Transcatheter Arterial Chemoembolization in Hepatocellular Carcinoma	Unknown status	NCT02253511	Phase 4	Cidan capsule
9	Transarterial Radioembolization Versus Chemoembolization for the Treatment of Advanced Hepatocellular Carcinoma	Unknown status	NCT02729506	Phase 4
10	A Randomized Controled Trial of Oral S-1 in Combination With Sequential Hepatic Arterial Infusion of Oxaliplatin After Transarterial Chemoembolization in Patients With Advanced Hepatocellular Carcinoma	Unknown status	NCT01997957	Phase 4	S-1
11	Hepatic Resection Versus Transarterial Chemoembolization as the Initial Treatment for Resectable Hepatocellular Carcinoma Beyond Milan Criteria	Unknown status	NCT02138981	Phase 4
12	Radiofrequency Ablation With or With Transcatheter Arterial Embolization for Hepatocellular Carcinoma	Unknown status	NCT00554905	Phase 4
13	Radiotherapy as an Adjuvant Therapy After Radiofrequency Ablation for Hepatocellular Carcinoma	Unknown status	NCT00557024	Phase 4
14	A Prospective, Randomized, Multicenter, Open-label, Exploratory Study of Utilizing of Peginterferon Alfa-2a on the Relapse Rate of the Subjects With Hepatocellular Carcinoma Who Have Been Treated by Resection	Unknown status	NCT03253250	Phase 4	ETV；TDF；ADV;Peginterferon Alfa-2a
15	Laparoscopic Surgery Versus Radiofrequency Ablation for Recurrent Hepatocellular Carcinoma After Initial Partial Hepatectomy: A Multicenter Experience	Unknown status	NCT02535117	Phase 4
16	Randomized, Open Label, Clinical Trial for GALNT14 Genotype - Guided, Sorafenib in Combination With TACE Therapy in Hepatocellular Carcinoma	Unknown status	NCT02504983	Phase 4	sorafenib
17	The Observation Of Safety And Survival Of Hepatocellular Carcinoma After Transcatheter Arterial Chemoembolization Combined With Anti-hepatitis B Virus Therapy	Unknown status	NCT01102335	Phase 4	Telbivudine
18	Effect of Babaodan in Preventing Tumor Recurrence After Hepatectomy for Hepatocellular Carcinoma: a Multicenter, Randomized, Placebo-controlled, Double-blind Trial	Unknown status	NCT03515369	Phase 4	Babaodan oral capsule;Placebo oral capsule
19	Comparison of Efficacy Between Sorafenib Monotherapy vs. Transarterial Chemoembolization -Sorafenib Sequential Therapy in Hepatocellular Carcinoma Patients With Extrahepatic Metastasis	Unknown status	NCT03518502	Phase 4	Sorafenib
20	A Prospective Clinical Trial of TACE Combined With Methylcantharidimide Tablets in the Treatment of Large and Unresectable Hepatocellular Carcinoma	Unknown status	NCT03996681	Phase 4	methylcantharidimide tablets
21	Prophylactic Administration of Antibiotics Before Radiofrequency Ablation for Hepatocellular Carcinoma: A Randomized Trial	Unknown status	NCT02534961	Phase 4	Cefazolin
22	Xihuang Capsules Prevention of Recurrence in Patients With Hepatocellular Carcinoma After Hepatectomy: A Multicenter Randomized Controlled Trial	Unknown status	NCT02399033	Phase 4	Xihuang Capsules
23	Hepatic Resection Versus Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma Complicated by Portal Vein Tumor Thrombosis.A Prospective and Randomized Clinical Trial	Unknown status	NCT01350206	Phase 4
24	Radiofrequency Ablation Versus Liver Resection for Elderly Patients With Hepatocellular Carcinoma (HCC) Within the Milan Criteria	Unknown status	NCT01570075	Phase 4
25	A Clinical Trail of Iodine[131I] Metuximab Injection With CIK Cells for Preventing Relapse and Metastasis of Hepatocellular Carcinoma	Unknown status	NCT01758679	Phase 4
26	Radiofrequency Ablation Combined With Transcatheter Arterial Chemoembolization Versus Radiofrequency Ablation Alone for Recurrent Hepatocellular Carcinoma	Unknown status	NCT01415063	Phase 4
27	Endoscopic Treatment Alone Versus Combined Propranolol and Endoscopic Treatment of Acute Variceal Hemorrhage in Patients With Hepatocellular Carcinoma	Unknown status	NCT01451658	Phase 4	propranolol
28	Investigator Initiated Study of Thymosin in HBV-related HCC	Unknown status	NCT02281266	Phase 4	thymalfasin;nucleoside analog (suggest to use entecavir)
29	Phase4, to Assess Time to Progression (TTP) and Safety Profile of Doxorubicin-Eluting-Bead Embolization(DEBDOX) in Patients With Advanced HCC	Unknown status	NCT02525380	Phase 4
30	Effects of Different Inhalational Anesthetic Agents on the Incidence of Clinical and Subclinical Acute Kidney Injury After Liver Resection Surgery: a Pilot Study	Unknown status	NCT02174575	Phase 4	Sevoflurane;Desflurane
31	Trial of Ablation of Small Hepatocellular Carcinomas in Patients of Cirrhosis	Unknown status	NCT01438437	Phase 4
32	Radiofrequency Ablation vs. Hepatic Resection for the Treatment of Hepatocellular Carcinomas Smaller Than 2 cm.A Prospective and Randomized Clinical Trial	Unknown status	NCT01351194	Phase 4
33	An Randomized and Controlled Study of Hepatic Arterial Infusion of Oxaliplatin and Fluorouracil Treatment of Advanced Primary Liver Cancer After TACE	Unknown status	NCT02557503	Phase 4	Oxaliplatin and fluorouracil
34	Clinical Trial of Cinobufacini Combined With Transarterial Chemoembolization (TACE) on Primary Liver Cancer	Unknown status	NCT03843229	Phase 4	Cinobufacini injection;cinobufacini tablet
35	A Prospective,Randomized Control Trial of Intraoperative Intraportal Chemotherapy (5-FU and Oxaliplatin) Combined With Adjuvant Chemotherapy to Prevent Liver Metastasis in Patients Receiving Curative Colorectal Cancer Resection.	Unknown status	NCT01972503	Phase 4	5-FU and oxaliplatin
36	Study of Cetuximab in Combination With Chemotherapy for the First Treatment of Metastatic Colorectal Cancer	Unknown status	NCT01564810	Phase 4	Cetuximab;chemotherapy of mFOLFOX6 or FOLFIRI
37	Phase IV Multi-Institutional Randomized Trial of Capecitabine Plus Oxaliplatin With Bevacizumab in Patients With Potentially Resectable Gastric Cancer With Liver Metastasis	Unknown status	NCT01962376	Phase 4	Oxaliplatin;Capecitabine;Oxaliplatin;Capecitabine;Bevacizumab
38	A Randomized Controlled Trial of TACE Hepatic Artery Infusion of Oxaliplatin and Raltitrexed Treatment of Colorectal Cancer With Liver Metastases	Unknown status	NCT02557490	Phase 4	oxaliplatin and raltitrexed
39	TAC vs TACE Plus folfox4 as the Treatment of Unresectalbe Liver Metastasis of Colorectal Cancer With Resection of the Primary Tumor: a Prospective, Randomized, Control Trial	Unknown status	NCT00868569	Phase 4
40	Phase IV Multi-Institutional Randomized Trial of Capecitabine Plus Oxaliplatin With Herceptin in Patients With Potentially Resectable HER-2 Positive Gastric Cancer With Liver Metastasis	Unknown status	NCT02380131	Phase 4	Oxaliplatin plus Capecitabine;Herceptin
41	A Prospective, Randomized, One-center Study Assessing Overall Survival Using RFA Plus Chemotherapy ± Target Therapy and Chemotherapy ± Target Therapy Alone in Patients With Unresectable Unresectable Colorectal Cancer Liver Metastases	Unknown status	NCT03127072	Phase 4	chemotherapy ± target therapy
42	Effect of Preoperative Administration of Oral Pregabalin on the Postoperative Analgesia in Patients Scheduled for Radiofrequency Ablationof Focal Lesions in the Liver	Unknown status	NCT03151213	Phase 4	Pregabalin 150mg
43	A Randomized Tril of Endoscopic Cyanoacrylate Obliteration vs. Nadolol	Unknown status	NCT00567216	Phase 4	Nadolol
44	Endoscopic Treatment Alone Versus Combined Propranolol and Endoscopic Treatment of Acute Variceal Hemorrhage in Patients With HCC:a Randomized Trial	Unknown status	NCT01298284	Phase 4	propranolol
45	G-CSF Alone or Combination With GM-CSF on Prevention and Treatment of Infection in Children With Malignant Tumor: a Prospective, Multicentre, Randomised Controlled Trial	Unknown status	NCT02933333	Phase 4
46	Transarterial Chemoembolization Versus Best Support for Unresectable Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis	Completed	NCT00646100	Phase 4
47	Clinical Research of in the Treatment of Unresectable Hepatocellular Carcinoma	Completed	NCT00829465	Phase 4	Licartin
48	Efficacy of Preoperative Transarterial Chemoembolization for Resectable Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis: A Prospective Non-Randomized Comparative Study	Completed	NCT01952353	Phase 4
49	Outcome of Transarterial Chemo-embolization (TACE) in Hepatocellular Carcinoma Patients With Partial Portal Vein Thrombosis	Completed	NCT03007212	Phase 4
50	Phase 4 Study of Peg-interferon Plus Ribavirin Therapy for Prevention of Hepatocellular Carcinoma	Completed	NCT00375661	Phase 4	interferon-alfa-2b and ribavirin

Search NIH Clinical Center for Hepatocellular Carcinoma

Inferred drug relations via UMLS ⁷¹ / NDF-RT ⁵⁰ :

Interferon Alfa-2a

Interferon Alfa-2b

INTERFERON ALFA-3N,HUMAN LEUKOCYTE DERIVED

interferon alfacon-1

Interferon gamma-1b

Interferons

peginterferon alfa-2a

peginterferon alfa-2b

Recombinant interferon beta-1a

Recombinant interferon beta-1b

regorafenib

sorafenib

Cell-based therapeutics:

Data from LifeMap, the Embryonic Development and Stem Cells Database

Read about Hepatocellular Carcinoma cell therapies at LifeMap Discovery.

Stem-cell-based therapeutic approaches for Hepatocellular Carcinoma:

Tumor infiltrating lymphocytes (TILs) for solid tumors

Embryonic/Adult Cultured Cells Related to Hepatocellular Carcinoma:

Tumor infiltrating lymphocytes PMIDs: 24329789 19342963 21498393 22996367 19304471 22555974 15800326 23650429 21325070 8170938 12242449 24218514 23904171

Cochrane evidence based reviews: liver neoplasms

Sources

Genetic Tests for Hepatocellular Carcinoma

Genetic tests related to Hepatocellular Carcinoma:

#	Genetic test	Affiliating Genes
1	Hepatocellular Carcinoma ²⁸	APC AXIN1 CASP8 CTNNB1 IGF2R MET PDGFRL PIK3CA TP53

Sources

Anatomical Context for Hepatocellular Carcinoma

Organs/tissues related to Hepatocellular Carcinoma:

FMA: Liver, Liver

MalaCards : Liver, T Cells, Bone Marrow, Myeloid, Skin, Lung, Colon

Sources

Publications for Hepatocellular Carcinoma

Articles related to Hepatocellular Carcinoma:

(show top 50) (show all 54579)

#	Title	Authors	PMID	Year
1	PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas. ⁵³ ⁵⁷ ⁵	Lee JW...Lee SH	15608678	2005
2	MicroRNA expression, survival, and response to interferon in liver cancer. ⁶² ⁴⁶ ⁵⁷	Ji J...Wang XW	19812400	2009
3	Beta-catenin mutations in hepatocellular carcinoma correlate with a low rate of loss of heterozygosity. ⁵³ ⁶² ⁵	Legoix P...Zucman-Rossi J	10435629	1999
4	Susceptibility to hepatocellular carcinoma is associated with genetic variation in the enzymatic detoxification of aflatoxin B1. ⁵³ ⁶² ⁵⁷	McGlynn KA...Ofori-Adjei D	7892276	1995
5	Inducing and exploiting vulnerabilities for the treatment of liver cancer. ⁶² ⁵⁷	Wang C...Bernards R	31578521	2019
6	Proteomics identifies new therapeutic targets of early-stage hepatocellular carcinoma. ⁶² ⁵⁷	Jiang Y...Chinese Human Proteome Project (CNHPP) Consortium	30814741	2019
7	Necroptosis microenvironment directs lineage commitment in liver cancer. ⁶² ⁵⁷	Seehawer M...Zender L	30209397	2018
8	Telomerase reverse transcriptase germline mutations and hepatocellular carcinoma in patients with nonalcoholic fatty liver disease. ⁶² ⁵	Donati B...Valenti L	28677271	2017
9	Detection of a recurrent DNAJB1-PRKACA chimeric transcript in fibrolamellar hepatocellular carcinoma. ⁶² ⁵⁷	Honeyman JN...Simon SM	24578576	2014
10	Oncofetal gene SALL4 in aggressive hepatocellular carcinoma. ⁶² ⁵⁷	Yong KJ...Tenen DG	23758232	2013
11	Exome sequencing of hepatitis B virus-associated hepatocellular carcinoma. ⁶² ⁵⁷	Huang J...Han ZG	22922871	2012
12	Inactivating mutations of the chromatin remodeling gene ARID2 in hepatocellular carcinoma. ⁶² ⁵⁷	Li M...Kinzler KW	21822264	2011
13	Genome-wide association study identifies a susceptibility locus for HCV-induced hepatocellular carcinoma. ⁶² ⁵⁷	Kumar V...Matsuda K	21499248	2011
14	Genome-wide association study identifies 1p36.22 as a new susceptibility locus for hepatocellular carcinoma in chronic hepatitis B virus carriers. ⁶² ⁵⁷	Zhang H...Zhou G	20676096	2010
15	Diet-induced hepatocellular carcinoma in genetically predisposed mice. ⁶² ⁵⁷	Hill-Baskin AE...Nadeau JH	19454484	2009
16	MicroRNA-23b mediates urokinase and c-met downmodulation and a decreased migration of human hepatocellular carcinoma cells. ⁵³ ⁶² ⁴⁶	Salvi A...Barlati S	19490101	2009
17	miR-34a inhibits migration and invasion by down-regulation of c-Met expression in human hepatocellular carcinoma cells. ⁵³ ⁶² ⁴⁶	Li N...Zheng X	19006648	2009
18	Astrocyte elevated gene-1 regulates hepatocellular carcinoma development and progression. ⁶² ⁵⁷	Yoo BK...Sarkar D	19221438	2009
19	Epidermal growth factor gene functional polymorphism and the risk of hepatocellular carcinoma in patients with cirrhosis. ⁶² ⁵⁷	Tanabe KK...Fuchs BC	18167406	2008
20	Cyclin G1 is a target of miR-122a, a microRNA frequently down-regulated in human hepatocellular carcinoma. ⁵³ ⁶² ⁴⁶	Gramantieri L...Negrini M	17616664	2007
21	Mutant p53 expression enhances drug resistance in a hepatocellular carcinoma cell line. ⁶² ⁵	Chan KT...Lung ML	15004724	2004
22	Interleukin 10 haplotype associated with increased risk of hepatocellular carcinoma. ⁶² ⁵⁷	Shin HD...Lee HS	12668613	2003
23	Molecular pathogenesis of human hepatocellular carcinoma. ⁶² ⁵⁷	Thorgeirsson SS...Grisham JW	12149612	2002
24	Gain of imprinting at chromosome 11p15: A pathogenetic mechanism identified in human hepatocarcinomas. ⁵³ ⁵⁷	Schwienbacher C...Negrini M	10779553	2000
25	AXIN1 mutations in hepatocellular carcinomas, and growth suppression in cancer cells by virus-mediated transfer of AXIN1. ⁵³ ⁵	Satoh S...Nakamura Y	10700176	2000
26	Molecular basis of severe gynecomastia associated with aromatase expression in a fibrolamellar hepatocellular carcinoma. ⁶² ⁵⁷	Agarwal VR...Bulun SE	9589695	1998
27	Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa. ⁶² ⁵	Bressac B...Ozturk M	1672732	1991
28	Mutational hotspot in the p53 gene in human hepatocellular carcinomas. ⁵³ ⁵	Hsu IC...Harris CC	1849234	1991
29	Loss of heterozygosity suggests tumor suppressor gene responsible for primary hepatocellular carcinoma. ⁶² ⁵⁷	Buetow KH...Govindarajah S	2573067	1989
30	Regional mapping to 4q32.1 by in situ hybridization of a DNA domain rearranged in human liver cancer. ⁶² ⁵⁷	Blanquet V...Turleau C	2847975	1988
31	Deletion in chromosome 11p associated with a hepatitis B integration site in hepatocellular carcinoma. ⁶² ⁵⁷	Rogler CE...Kew M	2996131	1985
32	Somatic PIK3CA Mutations in Sporadic Cerebral Cavernous Malformations. ⁵	Peyre M...Kalamarides M	34496175	2021
33	Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity. ⁵	Chang MT...Taylor BS	26619011	2016
34	Reactivation of multipotency by oncogenic PIK3CA induces breast tumour heterogeneity. ⁵	Van Keymeulen A...Blanpain C	26266985	2015
35	PIK3CA(H1047R) induces multipotency and multi-lineage mammary tumours. ⁵	Koren S...Bentires-Alj M	26266975	2015
36	Prospective enterprise-level molecular genotyping of a cohort of cancer patients. ⁵	MacConaill LE...Lindeman NI	25157968	2014
37	Oncofetal gene SALL4 in aggressive hepatocellular carcinoma. ⁵⁷	Suzuki E...Yokosuka O	24047070	2013
38	Acquired resistance to crizotinib from a mutation in CD74-ROS1. ⁵⁷	Gerlinger M...Swanton C	24047073	2013
39	Oncofetal gene SALL4 in aggressive hepatocellular carcinoma. ⁵⁷	Hopkins LJ...Houlihan DD	24047069	2013
40	Oncofetal gene SALL4 in aggressive hepatocellular carcinoma. ⁵⁷	Masuda S...Izpisua Belmonte JC	24047071	2013
41	Somatic gain-of-function mutations in PIK3CA in patients with macrodactyly. ⁵	Rios JJ...Ezaki M	23100325	2013
42	Liver transplantation for hepatocellular carcinoma in a patient with a novel telomerase mutation and steatosis. ⁵	Valenti L...Fracanzani AL	23000435	2013
43	Somatic mosaic activating mutations in PIK3CA cause CLOVES syndrome. ⁵	Kurek KC...Warman ML	22658544	2012
44	Mosaic overgrowth with fibroadipose hyperplasia is caused by somatic activating mutations in PIK3CA. ⁵	Lindhurst MJ...Semple RK	22729222	2012
45	hsa-miR-191 is a candidate oncogene target for hepatocellular carcinoma therapy. ⁶² ⁴⁶	Elyakim E...Yerushalmi N	20924108	2010
46	microRNA-22, downregulated in hepatocellular carcinoma and correlated with prognosis, suppresses cell proliferation and tumourigenicity. ⁶² ⁴⁶	Zhang J...Zhou W	20842113	2010
47	Association of a variant in MIR 196A2 with susceptibility to hepatocellular carcinoma in male Chinese patients with chronic hepatitis B virus infection. ⁶² ⁴⁶	Qi P...Gao CF	20188135	2010
48	miR-124 and miR-203 are epigenetically silenced tumor-suppressive microRNAs in hepatocellular carcinoma. ⁶² ⁴⁶	Furuta M...Inazawa J	19843643	2010
49	Effects of microRNA-29 on apoptosis, tumorigenicity, and prognosis of hepatocellular carcinoma. ⁶² ⁴⁶	Xiong Y...Zhuang SM	20041405	2010
50	MiR-222 overexpression confers cell migratory advantages in hepatocellular carcinoma through enhancing AKT signaling. ⁶² ⁴⁶	Wong QW...Wong N	20103675	2010

Sources

Genes for Hepatocellular Carcinoma

Genes/enhancers related to Hepatocellular Carcinoma (91 elite genes):

(show top 50) (show all 1093)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubMed IDs
1	PIK3CA	Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha	Protein Coding	1357.9	Molecular basis known ⁵⁷ Pathogenic/Likely pathogenic ⁵ Causative variation ⁷³ Genetic Tests ²⁸ Likely pathogenic ⁵ DISEASES inferred ¹⁴ ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Disorders Publications (show sections)	15016963 15520168 15608678 (more) 17673550 22658544 22729222 23100325 26266975 26266985 26619011 34496175 18181165 16331247 16184552
2	AXIN1	Axin 1	Protein Coding	1356.75	Molecular basis known ⁵⁷ Pathogenic ⁵ Causative variation ⁷³ Genetic Tests ²⁸ DISEASES inferred ¹⁴ ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Disorders Publications Summaries Pathways & Interactions (show sections)	10700176 11526492 18592156
3	TP53	Tumor Protein P53	Protein Coding	1090.13	Molecular basis known ⁵⁷ Pathogenic ⁵ Genetic Tests ²⁸ Likely pathogenic ⁵ DISEASES inferred ¹⁴ ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Disorders Publications Pathways & Interactions Functions (show sections)	1349102 1672732 1849234 (more) 26619011 15004724 25157968 12800224 7689531 12772781 1332921 9821791 8381223 8051396 8093350 7698586 20233581 8655704 8307460 1330867 11704835 11692157 15806265 15800979 9722210 1317262 1310637 1847999 17351803 11804744 8259041 8393124 10024676 18931711 17278226 15722574 12679912 8238731 8101139 8453727 18929532 15151767 12706878 11606857 16995981 10883667 1327523 16007066 1655254 8043159 7557882 8954175 9215122 9716224 9645455 9049201 8779541 7890286 7804430 8104947 8004579 19666408 15973077 14719122 12143201 11436649 9849479 15304126 14692445 12538486 11074891 10671685 10523694 9168988 8824565 8082236 15105048 14697131 12760798 12483005 10639517 10485485 9012469 9387269 8672994 8033311 8014109 8386823 19688691 18519672 17191126 1682737 19954744 16521213 15566504 14716820 12168936 10489124 12223131 10738214 10394883 9463584 9403027 9096590 8895490
4	CTNNB1	Catenin Beta 1	Protein Coding	1079.25	Molecular basis known ⁵⁷ Pathogenic/Likely pathogenic ⁵ Genetic Tests ²⁸ Likely pathogenic ⁵ DISEASES inferred ¹⁴ ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Disorders Publications Pathways & Interactions (show sections)	10435629 25157968 26619011 (more) 19728763 17908501 16094707 10811985 18282277 11429783 18294932 12969793 19290490 17510384 19719918 12198663 12692418 11443619 18922122 17785413 15580286 15563600 8675162 20460486 15131798 18720004 17487939 12499787 15362367 14687479 10836294 19411833 18842495 12203220 12481159 16368566 9458373 10580987 12603528 12447692 11839663 17452818 17283120 17030191 16465377 18246041 15067328 12830000 11477549 19887546 18030363 17006939 15965925 12893427 16314847 17275129 15355642 11906618 10487827 20347502 18264082 17690210 16843107 15814635 12512043 12375019 12167121 10700176 17927878 18592156 18313787 15305374 12601349 11267862 11169521 19635198 18803590 16465411 15067380 18313840 17443492 15064734 14517842 11819825 10980116 10201372 10597262 11526492 11238187 19849855 19671058 18701136 17964517 9683818 19383900 19401692 17657734 16897741 12883492 15795286
5	APC	APC Regulator Of WNT Signaling Pathway	Protein Coding	1076.99	Molecular basis known ⁵⁷ Pathogenic ⁵ Genetic Tests ²⁸ Likely pathogenic ⁵ DISEASES inferred ¹⁴ ¹⁴ ¹⁴ ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Disorders Publications Pathways & Interactions (show sections)	11466687 1423316 10692769 (more) 11929813 17030191 10435629 16843107 10700176 12893427 15067328 15842799 18673245
6	IGF2R	Insulin Like Growth Factor 2 Receptor	Protein Coding	1058.72	Molecular basis known ⁵⁷ Pathogenic ⁵ Genetic Tests ²⁸ Likely pathogenic ⁵ DISEASES inferred ¹⁴ ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications Summaries (show sections)	9722161 1337723 7639583 (more) 12736721 11981765 7753549 10347113 20477401 9294214 9570384
7	CASP8	Caspase 8	Protein Coding	1028.37	Molecular basis known ⁵⁷ Pathogenic ⁵ Genetic Tests ²⁸ DISEASES inferred ¹⁴ ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	15531912 20403046 17922191 (more) 16750275 20383464 15105837 17030378
8	PDGFRL	Platelet Derived Growth Factor Receptor Like	Protein Coding	1007.59	Molecular basis known ⁵⁷ Pathogenic ⁵ Genetic Tests ²⁸ DISEASES inferred ¹⁴ ¹⁴	7898930
9	MET	MET Proto-Oncogene, Receptor Tyrosine Kinase	Protein Coding	950.04	Molecular basis known ⁵⁷ Causative variation ⁷³ Genetic Tests ²⁸ DISEASES inferred ¹⁴ ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Disorders Publications Summaries (show sections)	8276372 7927256 8778194 (more) 16227408 10374571 9214452 10925356 12527708 18613405 17611703 11527416 19490101 9690121 11798848 16784653 7768498 19065669 19236112 14559814 9516398 16125074 9815784 19006648 16510587 20506063 17311762 8707284 8681452 8705780 16867270
	MET::MIR23B ⁴⁶	MIR23B Macro RNA (hsa-miR-23b) targets MET
	MET::MIR34A ⁴⁶	MIR34A Macro RNA (hsa-miR-34a) targets MET
10	TERT	Telomerase Reverse Transcriptase	Protein Coding	456.02	Pathogenic ⁵ Likely pathogenic ⁵ DISEASES inferred ¹⁴ ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	23000435 28677271 19627485 (more) 18753050 11944954 15143919 17244456 10732755 17212643 12926063 14991929 19639202 17175353 16793609 18281783 16237755 15387948 10087321 17159602 15867214 15849810 20459048 16729333 18683194 17307151 12974904 16792868 12813464 16298398
11	MIR21	MicroRNA 21	RNA Gene	443.27	Causal ⁴⁶ Unspecified ⁴⁶ DISEASES inferred ¹⁴ ¹⁴ ¹⁴ ¹⁴ GeneCards inferred via : Publications Pathways & Interactions (show sections)	18688024 19179615
12	MIR34A	MicroRNA 34a	RNA Gene	440.62	Causal ⁴⁶ Unspecified ⁴⁶ DISEASES inferred ¹⁴ ¹⁴ ¹⁴ ¹⁴ GeneCards inferred via : Publications Pathways & Interactions (show sections)	18942116 18176954
13	MIR155	MicroRNA 155	RNA Gene	439.24	Causal ⁴⁶ Unspecified ⁴⁶ DISEASES inferred ¹⁴ ¹⁴ ¹⁴ ¹⁴ GeneCards inferred via : Publications Pathways & Interactions (show sections)	19711427 17616664
14	MIR18A	MicroRNA 18a	RNA Gene	437.56	Causal ⁴⁶ Unspecified ⁴⁶ DISEASES inferred ¹⁴ ¹⁴ ¹⁴ ¹⁴ GeneCards inferred via : Publications Pathways & Interactions (show sections)	18688024 16331254
15	MIR200B	MicroRNA 200b	RNA Gene	436.4	Causal ⁴⁶ Unspecified ⁴⁶ DISEASES inferred ¹⁴ ¹⁴ ¹⁴ ¹⁴ GeneCards inferred via : Publications Pathways & Interactions (show sections)	18942116 16762633
16	MIR122	MicroRNA 122	RNA Gene	434.49	Causal ⁴⁶ Unspecified ⁴⁶ DISEASES inferred ¹⁴ ¹⁴ ¹⁴ ¹⁴ GeneCards inferred via : Publications (show sections)	18692484 19473441
17	ALB	Albumin	Protein Coding	434.3	Pathogenic ⁵ DISEASES inferred ¹⁴ ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	8781999 8130973 11676882 (more) 16015705 18054847 16842330 19572414 8271063 14571795 17987802 18201877 8137482 9215133 16023760 8738727 9257984 10364032 12558746 16595196 7678368 18727662 15265851 14703276 11051369 10960969 1311001 19234449 18755287 19473332 17103048 15304123 15043519 9365042 9362358 1708742 19950230 18379139 19695327 19632597 16460997 11369140 9486047 8950211 8201226 11358906 9577616 9512949 8675155 8697089 8148956 7694441 19285598 17977800 17295871 16914573 12868680 9870687 9462663 9188579 8800740 16706823 17666340 15189276 12939586 9621860 9597257 8721104 8168340 12828610 9255149 7693402 1313141 12703543 12645337 15998437
18	MIR17	MicroRNA 17	RNA Gene	433.32	Causal ⁴⁶ Unspecified ⁴⁶ DISEASES inferred ¹⁴ ¹⁴ ¹⁴ ¹⁴ GeneCards inferred via : Publications (show sections)	18688024 16924677
19	MIR221	MicroRNA 221	RNA Gene	431.73	Causal ⁴⁶ Unspecified ⁴⁶ DISEASES inferred ¹⁴ ¹⁴ ¹⁴ ¹⁴ GeneCards inferred via : Publications (show sections)	18521080 17616664
20	MIR224	MicroRNA 224	RNA Gene	430.59	Causal ⁴⁶ Unspecified ⁴⁶ DISEASES inferred ¹⁴ ¹⁴ ¹⁴ ¹⁴ GeneCards inferred via : Publications (show sections)	18319255 16331254
21	MIR93	MicroRNA 93	RNA Gene	430.27	Causal ⁴⁶ Unspecified ⁴⁶ DISEASES inferred ¹⁴ ¹⁴ ¹⁴ ¹⁴ GeneCards inferred via : Publications (show sections)	19486339 16924677
22	MIR143	MicroRNA 143	RNA Gene	430.21	Causal ⁴⁶ Unspecified ⁴⁶ DISEASES inferred ¹⁴ ¹⁴ ¹⁴ ¹⁴ GeneCards inferred via : Publications (show sections)	19472311 19473441
23	MIR146A	MicroRNA 146a	RNA Gene	429.41	Causal ⁴⁶ Unspecified ⁴⁶ DISEASES inferred ¹⁴ ¹⁴ ¹⁴ ¹⁴ GeneCards inferred via : Publications (show sections)	18711148 17616664
24	MIR223	MicroRNA 223	RNA Gene	429.4	Causal ⁴⁶ Unspecified ⁴⁶ DISEASES inferred ¹⁴ ¹⁴ ¹⁴ ¹⁴ GeneCards inferred via : Publications (show sections)	18555017 17616664
25	MIR222	MicroRNA 222	RNA Gene	429.3	Causal ⁴⁶ Unspecified ⁴⁶ DISEASES inferred ¹⁴ ¹⁴ ¹⁴ ¹⁴ GeneCards inferred via : Publications (show sections)	20103675 18319255
26	MIR25	MicroRNA 25	RNA Gene	428.81	Causal ⁴⁶ Unspecified ⁴⁶ DISEASES inferred ¹⁴ ¹⁴ ¹⁴ ¹⁴ GeneCards inferred via : Publications (show sections)	19486339 18319255
27	MAPK1	Mitogen-Activated Protein Kinase 1	Protein Coding	426.61	Pathogenic ⁵ DISEASES inferred ¹⁴ ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	16125074 19322916 18003605 (more) 19445727 18599034 18297306 16818510 19698189 16865242 19816936 16652141 14992744 19424594 16768106 19258520 16322093 17998146 18004740 11533045 17363567 18519678
28	RB1	RB Transcriptional Corepressor 1	Protein Coding	426.35	Pathogenic ⁵ DISEASES inferred ¹⁴ ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	11149028 17278226 8790559 (more) 9568177 8957064 15910504 8779541 15079795 9690121 1661338 18835587 15059540 1335479 12845670 14961299 7798888 16332962 11408803 8033150 15761978 7868063
29	MKI67	Marker Of Proliferation Ki-67	Protein Coding	425.85	Pathogenic ⁵ DISEASES inferred ¹⁴ ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	16007066 19351506 18294932 (more) 11074892 15623373 19104702 7804430 15133868 16255765 12883492 12960127 20062599 16260267 7545866 10347114 9588770 10398104
30	AR	Androgen Receptor	Protein Coding	425.75	Pathogenic ⁵ DISEASES inferred ¹⁴ ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	12600293 9387258 17191310 (more) 19201267 17230529 12208164 1849788 12154039 17149866 1334038 8895016 9062878 11263369
31	MIR27A	MicroRNA 27a	RNA Gene	422.57	Causal ⁴⁶ Unspecified ⁴⁶ DISEASES inferred ¹⁴ ¹⁴ ¹⁴ ¹⁴	18508316 19473441
32	MIR23A	MicroRNA 23a	RNA Gene	421.98	Causal ⁴⁶ Unspecified ⁴⁶ DISEASES inferred ¹⁴ ¹⁴ ¹⁴ ¹⁴	18508316 16924677
33	MIR195	MicroRNA 195	RNA Gene	421.97	Causal ⁴⁶ Unspecified ⁴⁶ DISEASES inferred ¹⁴ ¹⁴ ¹⁴ ¹⁴	19441017 16331254
34	HSP90AA1	Heat Shock Protein 90 Alpha Family Class A Member 1	Protein Coding	421.9	Pathogenic ⁵ DISEASES inferred ¹⁴ ¹⁴ GeneCards inferred via : Publications (show sections)
35	MIR20A	MicroRNA 20a	RNA Gene	421.81	Causal ⁴⁶ Unspecified ⁴⁶ DISEASES inferred ¹⁴ ¹⁴ ¹⁴ ¹⁴	18688024 16331254
36	MIR23B	MicroRNA 23b	RNA Gene	421.65	Causal ⁴⁶ Unspecified ⁴⁶ DISEASES inferred ¹⁴ ¹⁴ ¹⁴ ¹⁴	19490101 16924677
37	MIR181A1	MicroRNA 181a-1	RNA Gene	421.4	Causal ⁴⁶ Unspecified ⁴⁶ DISEASES inferred ¹⁴ ¹⁴ ¹⁴ ¹⁴	19585654 17616664
38	APOB	Apolipoprotein B	Protein Coding	420.12	Pathogenic ⁵ DISEASES inferred ¹⁴ ¹⁴ GeneCards inferred via : Publications (show sections)
39	ARID2	AT-Rich Interaction Domain 2	Protein Coding	420.04	Pathogenic ⁵ DISEASES inferred ¹⁴ ¹⁴ GeneCards inferred via : Publications (show sections)
40	MIR19A	MicroRNA 19a	RNA Gene	419.2	Causal ⁴⁶ Unspecified ⁴⁶ DISEASES inferred ¹⁴ ¹⁴ ¹⁴ ¹⁴	18688024 18176954
41	IGFBP1	Insulin Like Growth Factor Binding Protein 1	Protein Coding	418.81	Pathogenic ⁵ DISEASES inferred ¹⁴ ¹⁴ GeneCards inferred via : Publications (show sections)
42	SMG1	SMG1 Nonsense Mediated MRNA Decay Associated PI3K Related Kinase	Protein Coding	417.29	Pathogenic ⁵ DISEASES inferred ¹⁴ ¹⁴ GeneCards inferred via : Publications (show sections)
43	KEAP1	Kelch Like ECH Associated Protein 1	Protein Coding	413.89	Pathogenic ⁵ DISEASES inferred ¹⁴ ¹⁴
44	ARID1A	AT-Rich Interaction Domain 1A	Protein Coding	413.36	Pathogenic ⁵ DISEASES inferred ¹⁴ ¹⁴
45	TBP	TATA-Box Binding Protein	Protein Coding	411.53	Pathogenic ⁵ DISEASES inferred ¹⁴ ¹⁴
46	MIR181C	MicroRNA 181c	RNA Gene	411.27	Causal ⁴⁶ Unspecified ⁴⁶ DISEASES inferred ¹⁴ ¹⁴	19585654 17616664
47	MUC4	Mucin 4, Cell Surface Associated	Protein Coding	411.13	Pathogenic ⁵ DISEASES inferred ¹⁴ ¹⁴
48	TRADD	TNFRSF1A Associated Via Death Domain	Protein Coding	411.08	Pathogenic ⁵ DISEASES inferred ¹⁴ ¹⁴
49	MAP2K3	Mitogen-Activated Protein Kinase Kinase 3	Protein Coding	411.02	Pathogenic ⁵ DISEASES inferred ¹⁴ ¹⁴
50	DHFR	Dihydrofolate Reductase	Protein Coding	410.96	Pathogenic ⁵ DISEASES inferred ¹⁴ ¹⁴

Sources

Variations for Hepatocellular Carcinoma

ClinVar genetic disease variations for Hepatocellular Carcinoma:

⁵ (show top 50) (show all 606)

#	Gene	Name	Type	Significance	ClinVarId	dbSNP ID	Position
1	SET	NM_003011.4(SET):c.701A>G (p.Glu234Gly)	SNV	Other	438787	rs768759521	GRCh37: 9:131456212-131456212 GRCh38: 9:128693933-128693933
2	VDR	NM_000376.3(VDR):c.1056T>C (p.Ile352=)	SNV	Likely Risk Allele	308877	rs731236	GRCh37: 12:48238757-48238757 GRCh38: 12:47844974-47844974
3	VDR	NM_000376.3(VDR):c.1024+283G>A	SNV	Likely Risk Allele	1259287		GRCh37: 12:48239835-48239835 GRCh38: 12:47846052-47846052
4	PDGFRL	PDGRL, 2-BP DEL	DEL	Pathogenic	5469		GRCh37: GRCh38:
5	CTNNB1	NM_001904.4(CTNNB1):c.283C>T (p.Arg95Ter)	SNV	Pathogenic	265443	rs775104326	GRCh37: 3:41266486-41266486 GRCh38: 3:41224995-41224995
6	PIK3CA	NM_006218.4(PIK3CA):c.3139C>T (p.His1047Tyr)	SNV	Pathogenic Likely Pathogenic	39705	rs121913281	GRCh37: 3:178952084-178952084 GRCh38: 3:179234296-179234296
7	CTNNB1	NM_001904.4(CTNNB1):c.1041_1044del (p.Val349fs)	DEL	Pathogenic	801961	rs1575320216	GRCh37: 3:41268801-41268804 GRCh38: 3:41227310-41227313
8	CTNNB1	NM_001904.4(CTNNB1):c.1494dup (p.His499fs)	DUP	Pathogenic	499655	rs1553631896	GRCh37: 3:41275327-41275328 GRCh38: 3:41233836-41233837
9	AXIN1	NM_003502.4(AXIN1):c.1085_1116del (p.Val362fs)	DEL	Pathogenic	6037	rs587776627	GRCh37: 16:359973-360004 GRCh38: 16:309973-310004
10	CASP8	NM_001372051.1(CASP8):c.1228_1229del (p.Val410fs)	MICROSAT	Pathogenic	7761	rs587776665	GRCh37: 2:202149961-202149962 GRCh38: 2:201285238-201285239
11	IGF2R	NM_000876.4(IGF2R):c.4346G>T (p.Gly1449Val)	SNV	Pathogenic	14795	rs121434587	GRCh37: 6:160490993-160490993 GRCh38: 6:160069961-160069961
12	IGF2R	NM_000876.4(IGF2R):c.4391G>A (p.Gly1464Glu)	SNV	Pathogenic	14796	rs121434588	GRCh37: 6:160491038-160491038 GRCh38: 6:160070006-160070006
13	TP53	NM_000546.6(TP53):c.380C>T (p.Ser127Phe)	SNV	Pathogenic	182928	rs730881999	GRCh37: 17:7578550-7578550 GRCh38: 17:7675232-7675232
14	LOC109504725, AR	NM_000044.6(AR):c.171GCA[20] (p.Gln78_Gln80del)	MICROSAT	Pathogenic	210223	rs3032358	GRCh37: X:66765159-66765167 GRCh38: X:67545317-67545325
15	LOC108663993, ATXN1	NM_001128164.2(ATXN1):c.588GCA[12] (p.Gln208del)	MICROSAT	Pathogenic	210503	rs193922926	GRCh37: 6:16327916-16327918 GRCh38: 6:16327685-16327687
16	LOC108663993, ATXN1	NM_001128164.2(ATXN1):c.633_635del (p.His211del)	DEL	Pathogenic	210506	rs759132871	GRCh37: 6:16327907-16327909 GRCh38: 6:16327676-16327678
17	LOC108663993, ATXN1	NM_001128164.2(ATXN1):c.588GCA[14] (p.Gln208dup)	MICROSAT	Pathogenic	218439	rs193922926	GRCh37: 6:16327915-16327916 GRCh38: 6:16327684-16327685
18	USF3	NM_001009899.4(USF3):c.4383GCA[11] (p.Gln1478del)	MICROSAT	Pathogenic	218482	rs10606566	GRCh37: 3:113376111-113376113 GRCh38: 3:113657264-113657266
19	MAP2K3	NM_145109.3(MAP2K3):c.644T>G (p.Leu215Trp)	SNV	Pathogenic	218844	rs74575904	GRCh37: 17:21207813-21207813 GRCh38: 17:21304501-21304501
20	AR and overlap with 1 gene(s)	NM_000044.6(AR):c.171GCA[25] (p.Gln79_Gln80dup)	MICROSAT	Pathogenic	290422	rs3032358	GRCh37: X:66765158-66765159 GRCh38: X:67545316-67545317
21	MAPK1	NM_002745.5(MAPK1):c.964G>A (p.Glu322Lys)	SNV	Pathogenic	376450	rs1057519911	GRCh37: 22:22127164-22127164 GRCh38: 22:21772875-21772875
22	AQP7	NM_001170.3(AQP7):c.700C>A (p.Arg234Ser)	SNV	Pathogenic	402384	rs139024279	GRCh37: 9:33385690-33385690 GRCh38: 9:33385692-33385692
23	LOC108663996, TBP	NM_003194.5(TBP):c.228_229del (p.Gln77fs)	DEL	Pathogenic	403524	rs1491487452	GRCh37: 6:170871052-170871053 GRCh38: 6:170561964-170561965
24	TP53	NM_000546.6(TP53):c.747G>C (p.Arg249Ser)	SNV	Pathogenic	406598	rs28934571	GRCh37: 17:7577534-7577534 GRCh38: 17:7674216-7674216
25	LOC109504725, AR	NM_000044.6(AR):c.171GCA[19] (p.Gln77_Gln80del)	MICROSAT	Pathogenic	464796	rs3032358	GRCh37: X:66765159-66765170 GRCh38: X:67545317-67545328
26	AR and overlap with 1 gene(s)	NM_000044.6(AR):c.171GCA[26] (p.Gln78_Gln80dup)	MICROSAT	Pathogenic	464797		GRCh37: X:66765158-66765159 GRCh38: X:67545316-67545317
27	LOC109504725, AR	NM_000044.6(AR):c.171GCA[22] (p.Gln80del)	MICROSAT	Pathogenic	464798		GRCh37: X:66765159-66765161 GRCh38: X:67545317-67545319
28	LOC108663996, TBP	NM_003194.5(TBP):c.216_218del (p.Gln95del)	DEL	Pathogenic	522261	rs71815788	GRCh37: 6:170871038-170871040 GRCh38: 6:170561950-170561952
29	ATXN1 and overlap with 1 gene(s)	NM_001128164.2(ATXN1):c.636GCA[16] (p.Gln224_Gln225dup)	MICROSAT	Pathogenic	522332	rs751421308	GRCh37: 6:16327864-16327865 GRCh38: 6:16327633-16327634
30	APC	NM_000038.6(APC):c.1695del (p.Val566fs)	DEL	Pathogenic	840	rs397514032	GRCh37: 5:112164620-112164620 GRCh38: 5:112828923-112828923
31	TERT	NM_198253.3(TERT):c.2004G>C (p.Glu668Asp)	SNV	Pathogenic	268081	rs1554040964	GRCh37: 5:1279532-1279532 GRCh38: 5:1279417-1279417
32	PIK3CA	NM_006218.4(PIK3CA):c.3203dup (p.Asn1068fs)	DUP	Pathogenic	13658	rs587776802	GRCh37: 3:178952146-178952147 GRCh38: 3:179234358-179234359
33	ARID1A	NM_006015.6(ARID1A):c.114GGC[4] (p.Ala45del)	MICROSAT	Pathogenic	591383	rs587779737	GRCh37: 1:27023008-27023010 GRCh38: 1:26696517-26696519
34	TP53	NM_000546.6(TP53):c.267dup (p.Ser90fs)	DUP	Pathogenic	634762	rs587783062	GRCh37: 17:7579419-7579420 GRCh38: 17:7676101-7676102
35	TAOK2	NM_016151.4(TAOK2):c.1140GGA[5] (p.Glu392del)	MICROSAT	Pathogenic	773579	rs368747234	GRCh37: 16:29994531-29994533 GRCh38: 16:29983210-29983212
36	USF3	NM_001009899.4(USF3):c.3047dup (p.Asn1016fs)	DUP	Pathogenic	805968	rs78597857	GRCh37: 3:113377481-113377482 GRCh38: 3:113658634-113658635
37	AR and overlap with 1 gene(s)	NM_000044.6(AR):c.171GCA[27] (p.Gln77_Gln80dup)	MICROSAT	Pathogenic	1168151		GRCh37: X:66765158-66765159 GRCh38: X:67545316-67545317
38	MAPK1	NM_002745.5(MAPK1):c.5CGG[7] (p.Ala7dup)	MICROSAT	Pathogenic	1174634		GRCh37: 22:22221708-22221709 GRCh38: 22:21867418-21867419
39	USF3	NM_001009899.4(USF3):c.4383GCA[9] (p.Gln1476_Gln1478del)	MICROSAT	Pathogenic	1174824		GRCh37: 3:113376111-113376119 GRCh38: 3:113657264-113657272
40	ATXN1 and overlap with 1 gene(s)	NM_001128164.2(ATXN1):c.636GCA[15] (p.Gln225dup)	MICROSAT	Pathogenic	1174970		GRCh37: 6:16327864-16327865 GRCh38: 6:16327633-16327634
41	DSPP	NM_014208.3(DSPP):c.3264_3290del (p.Asn1092_Ser1100del)	DEL	Pathogenic	1181538		GRCh37: 4:88537073-88537099 GRCh38: 4:87615921-87615947
42	DSPP	NM_014208.3(DSPP):c.3506_3507insTGACAGCAGCGACAGCAG (p.1152DSS[11])	MICROSAT	Pathogenic	1193978		GRCh37: 4:88537306-88537307 GRCh38: 4:87616154-87616155
43	DSPP	NM_014208.3(DSPP):c.2036_2053dup (p.Ser679_Ser684dup)	DUP	Pathogenic	1206200		GRCh37: 4:88535832-88535833 GRCh38: 4:87614680-87614681
44	LOC108663993, ATXN1	NM_001128164.2(ATXN1):c.636GCA[12] (p.Gln224_Gln225del)	MICROSAT	Pathogenic	1206220		GRCh37: 6:16327865-16327870 GRCh38: 6:16327634-16327639
45	DSPP	NM_014208.3(DSPP):c.3461_3462insCGATAGCAGCGACAGCAG (p.1152DSS[11])	MICROSAT	Pathogenic	1222757		GRCh37: 4:88537261-88537262 GRCh38: 4:87616109-87616110
46	DSPP	NM_014208.3(DSPP):c.3339_3347del (p.1095DSS[8])	DEL	Pathogenic	1224948		GRCh37: 4:88537151-88537159 GRCh38: 4:87615999-87616007
47	DSPP	NM_014208.3(DSPP):c.2214_2231del (p.Asn739_Ser744del)	DEL	Pathogenic	1233150		GRCh37: 4:88536014-88536031 GRCh38: 4:87614862-87614879
48	DSPP	NM_014208.3(DSPP):c.3102CGATAGCAGTGACAGCAG[2] (p.1032DSS[6])	MICROSAT	Pathogenic	1235701		GRCh37: 4:88536902-88536919 GRCh38: 4:87615750-87615767
49	DSPP	NM_014208.3(DSPP):c.3069_3086del (p.1017NSSDSS[2])	DEL	Pathogenic	1239462		GRCh37: 4:88536869-88536886 GRCh38: 4:87615717-87615734
50	DSPP	NM_014208.3(DSPP):c.3339_3419del (p.Asn1122_Ser1148del)	DEL	Pathogenic	1260466		GRCh37: 4:88537152-88537232 GRCh38: 4:87616000-87616080

UniProtKB/Swiss-Prot genetic disease variations for Hepatocellular Carcinoma:

⁷³ (show all 21)

#	Symbol	AA change	Variation ID	SNP ID
1	AXIN1	p.Leu106Arg	VAR_015589
2	AXIN1	p.Pro345Leu	VAR_015590	rs779951904
3	AXIN1	p.Gly425Ser	VAR_015591	rs116350678
4	AXIN1	p.Gly650Ser	VAR_015592	rs117208012
5	CDKN3	p.Trp31Arg	VAR_013842
6	CDKN3	p.Phe78Leu	VAR_013843
7	CDKN3	p.Cys79Tyr	VAR_013844
8	CDKN3	p.Asn91Lys	VAR_013845	rs760687800
9	CDKN3	p.Asp94Val	VAR_013846
10	CDKN3	p.Leu95Phe	VAR_013847
11	CDKN3	p.Ile108Val	VAR_013848	rs144479038
12	CDKN3	p.Asn187Ser	VAR_013849
13	CDKN3	p.Lys195Ile	VAR_013850
14	MET	p.Thr1173Ile	VAR_032490	rs121913675
15	MET	p.Lys1244Arg	VAR_032492	rs121913677
16	MET	p.Met1250Ile	VAR_032493	rs121913676
17	MTUS1	p.Gln75Lys	VAR_035173	rs61733703
18	MTUS1	p.Ala563Ser	VAR_035178
19	MTUS1	p.Asn873His	VAR_035180	rs187103704
20	MTUS1	p.Gln1201Arg	VAR_035184	rs567116808
21	PIK3CA	p.Glu545Ala	VAR_026176	rs121913274

Cosmic variations for Hepatocellular Carcinoma:

⁸ (show top 50) (show all 15388)

#	Cosmic Mut ID	Gene Symbol	COSMIC Disease Classification (Primary site, Site subtype, Primary histology, Histology subtype)	Mutation CDS	Mutation AA	GRCh38 Location	Conf
1	COSM97724722	ZXDB	liver,NS,carcinoma,hepatocellular carcinoma	c.1308C>A	p.D436E	23:57593356-57593356	55
2	COSM94430614	ZSWIM1	liver,NS,carcinoma,hepatocellular carcinoma	c.1399A>C	p.S467R	20:45883991-45883991	55
3	COSM94436083	ZSWIM1	liver,NS,carcinoma,hepatocellular carcinoma	c.1399A>C	p.S467R	20:45883991-45883991	55
4	COSM94063771	ZSCAN20	liver,NS,carcinoma,hepatocellular carcinoma	c.2314G>T	p.G772W	1:33494658-33494658	55
5	COSM88264637	ZRSR2	liver,NS,carcinoma,hepatocellular carcinoma	c.304G>T	p.E102*	23:15803788-15803788	55
6	COSM102741209	ZNRF3	liver,NS,carcinoma,hepatocellular carcinoma	c.859A>G	p.M287V	22:29049340-29049340	55
7	COSM131494492	ZNRF3	liver,NS,carcinoma,hepatocellular carcinoma	c.1159A>G	p.M387V	22:29049340-29049340	55
8	COSM103081572	ZNRF3	liver,NS,carcinoma,hepatocellular carcinoma	c.859A>G	p.M287V	22:29049340-29049340	55
9	COSM95977701	ZNFX1	liver,NS,carcinoma,hepatocellular carcinoma	c.2580G>A	p.L860=	20:49257501-49257501	55
10	COSM102131817	ZNFX1	liver,NS,carcinoma,hepatocellular carcinoma	c.2580G>A	p.L860=	20:49257501-49257501	55
11	COSM95960776	ZNFX1	liver,NS,carcinoma,hepatocellular carcinoma	c.2580G>A	p.L860=	20:49257501-49257501	55
12	COSM113317148	ZNF853	liver,NS,carcinoma,hepatocellular carcinoma	c.1610G>T	p.G537V	7:6622601-6622601	55
13	COSM99592496	ZNF829	liver,NS,carcinoma,hepatocellular carcinoma	c.829T>A	p.F277I	19:36891962-36891962	55
14	COSM128686611	ZNF829	liver,NS,carcinoma,hepatocellular carcinoma	c.1072T>A	p.F358I	19:36891962-36891962	55
15	COSM123358576	ZNF827	liver,NS,carcinoma,hepatocellular carcinoma	c.691C>T	p.L231=	4:145885684-145885684	55
16	COSM123949383	ZNF827	liver,NS,carcinoma,hepatocellular carcinoma	c.1741C>T	p.L581=	4:145885684-145885684	55
17	COSM101741672	ZNF827	liver,NS,carcinoma,hepatocellular carcinoma	c.1741C>T	p.L581=	4:145885684-145885684	55
18	COSM86004822	ZNF653	liver,NS,carcinoma,hepatocellular carcinoma	c.1553A>C	p.H518P	19:11485673-11485673	55
19	COSM98561269	ZNF615	liver,NS,carcinoma,hepatocellular carcinoma	c.141G>A	p.V47=	19:52002156-52002156	55
20	COSM142353152	ZNF615	liver,NS,carcinoma,hepatocellular carcinoma	c.141G>A	p.V47=	19:52002156-52002156	55
21	COSM142221290	ZNF615	liver,NS,carcinoma,hepatocellular carcinoma	c.141G>A	p.V47=	19:52002156-52002156	55
22	COSM99854658	ZNF615	liver,NS,carcinoma,hepatocellular carcinoma	c.156G>A	p.V52=	19:52002156-52002156	55
23	COSM139729931	ZNF615	liver,NS,carcinoma,hepatocellular carcinoma	c.141G>A	p.V47=	19:52002156-52002156	55
24	COSM141470046	ZNF615	liver,NS,carcinoma,hepatocellular carcinoma	c.141G>A	p.V47=	19:52002156-52002156	55
25	COSM141819438	ZNF615	liver,NS,carcinoma,hepatocellular carcinoma	c.141G>A	p.V47=	19:52002156-52002156	55
26	COSM145038099	ZNF615	liver,NS,carcinoma,hepatocellular carcinoma	c.141G>A	p.V47=	19:52002156-52002156	55
27	COSM91868668	ZNF536	liver,NS,carcinoma,hepatocellular carcinoma	c.3900G>T	p.K1300N	19:30557161-30557161	55
28	COSM91880764	ZNF536	liver,NS,carcinoma,hepatocellular carcinoma	c.2171-78T>G	p.?	19:30534769-30534769	55
29	COSM140721836	ZNF521	liver,NS,carcinoma,hepatocellular carcinoma	c.2998+205G>A	p.?	18:25194955-25194955	55
30	COSM131506983	ZNF521	liver,NS,carcinoma,hepatocellular carcinoma	c.3658+205G>A	p.?	18:25194955-25194955	55
31	COSM94799980	ZNF521	liver,NS,carcinoma,hepatocellular carcinoma	c.3658+205G>A	p.?	18:25194955-25194955	55
32	COSM90582798	ZNF518B	liver,NS,carcinoma,hepatocellular carcinoma	c.1624G>T	p.E542*	4:10444705-10444705	55
33	COSM87577038	ZNF462	liver,NS,carcinoma,hepatocellular carcinoma	c.6715G>T	p.V2239L	9:106974156-106974156	55
34	COSM109096265	ZNF462	liver,NS,carcinoma,hepatocellular carcinoma	c.3433G>T	p.V1145L	9:106974156-106974156	55
35	COSM104985080	ZNF385B	liver,NS,carcinoma,hepatocellular carcinoma	c.298+23785G>T	p.?	2:179745718-179745718	55
36	COSM104427909	ZNF385B	liver,NS,carcinoma,hepatocellular carcinoma	c.20G>T	p.S7I	2:179745718-179745718	55
37	COSM151538615	ZNF385B	liver,NS,carcinoma,hepatocellular carcinoma	c.253+23785G>T	p.?	2:179745718-179745718	55
38	COSM127708351	ZNF345	liver,NS,carcinoma,hepatocellular carcinoma	c.47-856A>T	p.?	19:36891962-36891962	55
39	COSM135887725	ZNF276	liver,NS,carcinoma,hepatocellular carcinoma	c.1168C>G	p.L390V	16:89734008-89734008	55
40	COSM84511025	ZNF276	liver,NS,carcinoma,hepatocellular carcinoma	c.1219C>G	p.L407V	16:89734008-89734008	55
41	COSM111609487	ZNF276	liver,NS,carcinoma,hepatocellular carcinoma	c.1444C>G	p.L482V	16:89734008-89734008	55
42	COSM92353291	ZNF26	liver,NS,carcinoma,hepatocellular carcinoma	c.1010C>T	p.T337I	12:133010889-133010889	55
43	COSM130415812	ZNF26	liver,NS,carcinoma,hepatocellular carcinoma	c.950C>T	p.T317I	12:133010889-133010889	55
44	COSM88697750	ZNF217	liver,NS,carcinoma,hepatocellular carcinoma	c.*194A>T	p.?	20:53569094-53569094	55
45	COSM95253159	ZNF217	liver,NS,carcinoma,hepatocellular carcinoma	c.*194A>T	p.?	20:53569094-53569094	55
46	COSM94505616	ZMYND12	liver,NS,carcinoma,hepatocellular carcinoma	c.425-1G>T	p.?	1:42440026-42440026	55
47	COSM89943752	ZMYM4	liver,NS,carcinoma,hepatocellular carcinoma	c.86-8201G>T	p.?	1:35350724-35350724	55
48	COSM101398456	ZIC2	liver,NS,carcinoma,hepatocellular carcinoma	c.-18C>T	p.?	13:99982047-99982047	55
49	COSM113521587	ZGPAT	liver,NS,carcinoma,hepatocellular carcinoma	c.*197C>A	p.?	20:63736116-63736116	55
50	COSM94679661	ZGPAT	liver,NS,carcinoma,hepatocellular carcinoma	c.*197C>A	p.?	20:63736116-63736116	55

Copy number variations for Hepatocellular Carcinoma from CNVD:

⁶ (show top 50) (show all 259)

#	CNVD ID	Chromosome	Start	End	Type	Gene Symbol	CNVD Disease
1	13772	1	1	34600000	Deletion		Hepatocellular carcinoma
2	14513	1	109179833	109180141	Copy number	EEIG2	Hepatocellular carcinoma
3	14515	1	109194253	109194520	Copy number	HENMT1	Hepatocellular carcinoma
4	16438	1	124300000	247249719	Gain		Hepatocellular carcinoma
5	17401	1	142600000	165500000	Amplification		Hepatocellular carcinoma
6	17404	1	142600000	207200000	Gain		Hepatocellular carcinoma
7	19328	1	149600000	153300000	Gain	ADAR	Liver carcinoma
8	19329	1	149600000	153300000	Gain	C1orf43	Liver carcinoma
9	19330	1	149600000	153300000	Gain	HAX1	Liver carcinoma
10	19331	1	149600000	163800000	Gain		Hepatocellular carcinoma
11	20083	1	15300000	184000000	Gain	TAGLN2	Hepatocellular carcinoma
12	20610	1	153300000	154800000	Gain	CCT3	Liver carcinoma
13	20847	1	154800000	157300000	Gain	CD1C	Liver carcinoma
14	20883	1	155000000	165500000	Amplification		Hepatocellular carcinoma
15	21205	1	157300000	158800000	Gain	NCSTN	Liver carcinoma
16	21983	1	163800000	165500000	Gain		Hepatocellular carcinoma
17	22134	1	165500000	185800000	Amplification		Hepatocellular carcinoma
18	23681	1	172900000	185800000	Amplification		Hepatocellular carcinoma
19	25105	1	184000000	212100000	Loss	PTPRC	Hepatocellular carcinoma
20	25628	1	192100000	197500000	Gain	CFHR2	Liver carcinoma
21	26151	1	197500000	205300000	Gain		Hepatocellular carcinoma
22	26278	1	198700000	214500000	Amplification		Hepatocellular carcinoma
23	26283	1	198700000	249250621	Gain		Hepatocellular carcinoma
24	28499	1	222700000	225100000	Gain	PYCR2	Liver carcinoma
25	29827	1	236600000	243700000	Amplification		Hepatocellular carcinoma
26	29867	1	237459374	237459731	Copy number	RYR2	Hepatocellular carcinoma
27	32947	1	40710846	40711321	Copy number		Hepatocellular carcinoma
28	33594	1	46500000	60900000	Loss	TGFBR3	Hepatocellular carcinoma
29	33953	1	50700000	61300000	Deletion		Hepatocellular carcinoma
30	34470	8	101232014	101235406	Copy number	POLR2K	Liver carcinoma
31	35820	1	67790665	67791040	Copy number	IL12RB2	Hepatocellular carcinoma
32	35832	1	67906093	67906510	Copy number		Hepatocellular carcinoma
33	36108	1	7200000	16200000	Copy number	MTOR	Hepatocellular carcinoma
34	37059	1	84900000	117800000	Deletion		Hepatocellular carcinoma
35	38186	10	1	6700000	Gain	AKR1C3	Hepatocellular carcinoma
36	38902	10	105800000	135534747	Amplification		Hepatocellular carcinoma
37	39998	10	12300000	17300000	Loss	MRC1	Hepatocellular carcinoma
38	42451	10	34400000	38000000	Amplification	CCNY	Hepatocellular carcinoma
39	42452	10	34400000	38000000	Amplification	CREM	Hepatocellular carcinoma
40	42453	10	34400000	38000000	Amplification	CUL2	Hepatocellular carcinoma
41	42454	10	34400000	38000000	Amplification	GJD4	Hepatocellular carcinoma
42	42455	10	34400000	38000000	Amplification	FZD8	Hepatocellular carcinoma
43	42456	10	34400000	38000000	Amplification	PARD3	Hepatocellular carcinoma
44	42799	10	40200000	42300000	Deletion		Hepatocellular carcinoma
45	48325	11	1	21700000	Amplification		Hepatocellular carcinoma
46	48353	11	1	2800000	Copy number	IGF2	Hepatocellular carcinoma
47	49881	11	111568063	111568201	Copy number	SIK2	Hepatocellular carcinoma
48	50022	11	112800000	127400000	Loss	SORL1	Hepatocellular carcinoma
49	57131	11	63100000	76700000	Loss	ESRRA	Hepatocellular carcinoma
50	57452	11	63400000	77100000	Deletion		Hepatocellular carcinoma

Sources

Expression for Hepatocellular Carcinoma

Genes differentially expressed in tissues of Hepatocellular Carcinoma patients vs. healthy controls: ³⁵

#	Gene	Description	Tissue	Up/Dn	Fold Change (log2)
1	EIF3H	eukaryotic translation initiation factor 3 subunit H	Liver	+	4.39
2	C9	complement C9	Liver	-	4.36
3	UBD	ubiquitin D	Liver	+	3.39
4	PSMD6	proteasome 26S subunit, non-ATPase 6	Liver	+	3.23

Search GEO for disease gene expression data for Hepatocellular Carcinoma.

Sources

Pathways for Hepatocellular Carcinoma

Pathways related to Hepatocellular Carcinoma according to GeneCards Suite gene sharing:

(show all 34)

#	Super pathways	Score	Top Affiliating Genes
1	Alzheimer's disease and miRNA effects ⁷⁴ Show member pathways Alzheimer's disease ⁷⁴	12.76	PIK3CA CTNNB1 CASP8 AXIN1 APC
2	ncRNAs involved in Wnt signaling in hepatocellular carcinoma ⁷⁴ Show member pathways lncRNA in canonical Wnt signaling and colorectal cancer ⁷⁴ Wnt signaling ⁷⁴ Wnt signaling pathway and pluripotency ⁷⁴ Wnt Signaling Pathways ⁶⁵	12.73	APC AXIN1 CTNNB1 MIR18A TP53
3	Endometrial cancer ⁷⁴ Show member pathways Chromosomal and microsatellite instability in colorectal cancer ⁷⁴ Melanoma ⁷⁴ Non-small cell lung cancer ⁷⁴ Pancreatic adenocarcinoma pathway ⁷⁴ Signal transduction PTEN pathway ²²	12.59	TP53 PIK3CA CTNNB1 CASP8 AXIN1 APC
4	Overview of interferons-mediated signaling pathway ⁷⁴ Show member pathways all-trans-Retinoic Acid Mediated Apoptosis ⁶⁴ Cytokine Network ⁶⁴ Immune response IFN alpha/beta signaling pathway ²² Interferon alpha/beta signaling ⁶⁶ Jak/STAT Signaling Pathway ⁶⁵ Regulation of IFNA/IFNB signaling ⁶⁶ Type III interferon signaling ⁷⁴	12.53	CASP8 IGF2R MET PIK3CA TERT TP53
5	Malignant pleural mesothelioma ⁷⁴	12.41	TP53 TERT PIK3CA MET CTNNB1 AXIN1
6	Development EGFR signaling pathway ²² Show member pathways Development ERBB-family signaling ²² EGF Pathway ⁶⁴ EGFR Signaling Pathway ⁶⁷ ErbB receptor signaling network ⁶¹	12.4	TP53 PIK3CA CTNNB1 CASP8
7	Hepatocyte growth factor receptor signaling ⁷⁴ Show member pathways Apoptosis and survival Anti-apoptotic action of membrane-bound ESR1 ²² Apoptosis and survival NGF signaling pathway ²² Apoptosis and survival Role of CDK5 in neuronal death and survival ²² Development HGF signaling pathway ²² Development Neurotrophin family signaling ²² Drug-mediated inhibition of MET activation ⁶⁶ MET activates PTPN11 ⁶⁶ MET activates STAT3 ⁶⁶ PLC-gamma1 signalling ⁶⁶ Trk receptor signaling mediated by PI3K and PLC-gamma ⁶¹ TRKA activation by NGF ⁶⁶	12.38	TP53 PIK3CA MET CTNNB1
8	WNT Signaling ⁶⁴	12.35	TP53 CTNNB1 AXIN1 APC
9	Breast cancer pathway ⁷⁴ Show member pathways Embryonic stem cell pluripotency pathways ⁷⁴	12.34	TP53 PIK3CA CTNNB1 AXIN1 APC
10	NF-kappaB Pathway ⁷⁰ Show member pathways Akt Pathway ⁷⁰ Apoptosis Pathway ⁷⁰	12.26	TP53 PIK3CA MET IGF2R CTNNB1 CASP8
11	MAPK Signaling: Mitogens ⁶⁵ Show member pathways Akt Signaling Pathway ⁶⁵	12.14	TP53 PIK3CA MET IGF2R
12	Presenilin-Mediated Signaling ⁶⁴	12.01	CTNNB1 CASP8 AXIN1 APC
13	mTOR Signaling ⁶⁵	11.94	APC AXIN1 IGF2R MET TP53
14	Small cell lung cancer ⁷⁴	11.82	TP53 PIK3CA CASP8
15	Overlap between signal transduction pathways contributing to LMNA laminopathies ⁷⁴ Show member pathways Influence of laminopathies on Wnt signaling ⁷⁴	11.8	CTNNB1 AXIN1 APC
16	Thyroid hormones production and peripheral downstream signaling effects ⁷⁴	11.74	TP53 PIK3CA CTNNB1
17	DNA damage response (only ATM dependent) ⁷⁴	11.73	TP53 PIK3CA CTNNB1 AXIN1 APC
18	mTOR Pathway ⁷⁰ Show member pathways TGF-beta Pathway ⁷⁰	11.71	TP53 PIK3CA IGF2R
19	Cell differentiation - expanded index ⁷⁴ Show member pathways Cell differentiation - index ⁷⁴	11.7	MIR221 MIR17 MIR155
20	Regulation of nuclear beta catenin signaling and target gene transcription ⁶¹	11.64	TERT CTNNB1 APC
21	Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met) ⁶¹	11.61	PIK3CA MET CTNNB1 APC
22	Physico-chemical features and toxicity-associated pathways ⁷⁴	11.59	CTNNB1 AXIN1 APC
23	Copper homeostasis ⁷⁴ Show member pathways Copper metabolism ⁷⁴ Defective SLC11A2 causes hypochromic microcytic anemia, with iron overload 1 (AHMIO1) ⁶⁶	11.54	TP53 PIK3CA APC
24	miRNAs involvement in the immune response in sepsis ⁷⁴	11.53	MIR21 MIR200B MIR155 MIR122
25	Hepatitis C and hepatocellular carcinoma ⁷⁴	11.51	TP53 MIR34A MIR155
26	IL-18 signaling pathway ⁷⁴	11.46	TP53 CTNNB1 CASP8
27	Interactions between immune cells and microRNAs in tumor microenvironment ⁷⁴	11.43	MIR34A MIR21 MIR200B
28	Presenilin action in Notch and Wnt signaling ⁶¹	11.41	CTNNB1 AXIN1 APC
29	Head and neck squamous cell carcinoma ⁷⁴	11.22	TP53 TERT PIK3CA CTNNB1 CASP8
30	N-cadherin signaling events ⁶¹	11.19	PIK3CA CTNNB1 AXIN1
31	Degradation of beta catenin ⁶¹ Show member pathways APC truncation mutants are not K63 polyubiquitinated ⁶⁶ Canonical Wnt signaling pathway ⁶¹	11.16	CTNNB1 AXIN1 APC
32	Extracellular vesicle-mediated signaling in recipient cells ⁷⁴	10.9	MET CTNNB1 AXIN1 APC
33	Regulation of Wnt / B-catenin signaling by small molecule compounds ⁷⁴	10.86	CTNNB1 AXIN1 APC
34	miRNAs involved in DNA damage response ⁷⁴	10.85	TP53 MIR221 MIR21 MIR18A MIR17

Sources

GO Terms for Hepatocellular Carcinoma

Cellular components related to Hepatocellular Carcinoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	Wnt signalosome	GO:1990909	9.73	CTNNB1 AXIN1 APC
2	beta-catenin destruction complex	GO:0030877	9.63	CTNNB1 AXIN1 APC
3	RISC complex	GO:0016442	9.53	MIR224 MIR221 MIR21 MIR200B MIR18A MIR17
4	extracellular vesicle	GO:1903561	9.35	MIR34A MIR221 MIR21 MIR17 MIR122

Biological processes related to Hepatocellular Carcinoma according to GeneCards Suite gene sharing:

(show all 19)

#	Name	GO ID	Score	Top Affiliating Genes
1	negative regulation of apoptotic process	GO:0043066	10.16	TP53 TERT MIR221 MIR21 MIR200B CTNNB1
2	miRNA-mediated gene silencing	GO:0035195	10.16	MIR34A MIR224 MIR221 MIR21 MIR200B MIR18A
3	cellular response to hypoxia	GO:0071456	10.02	TP53 TERT MIR34A MIR17
4	positive regulation of protein kinase B signaling	GO:0051897	10	PIK3CA MIR221 MIR21 MET
5	negative regulation of angiogenesis	GO:0016525	9.89	MIR34A MIR21 MIR200B CTNNB1
6	negative regulation of miRNA maturation	GO:1903799	9.88	TP53 TERT
7	positive regulation of epithelial to mesenchymal transition	GO:0010718	9.88	MIR221 MIR21 CTNNB1
8	positive regulation of apoptotic process	GO:0043065	9.77	TP53 MIR221 MIR21 MIR200B IGF2R CTNNB1
9	positive regulation of vascular associated smooth muscle cell migration	GO:1904754	9.73	TERT MIR221 MIR21
10	positive regulation of vascular associated smooth muscle cell proliferation	GO:1904707	9.72	TERT MIR221 MIR21 MIR17
11	positive regulation of cardiac muscle cell apoptotic process	GO:0010666	9.71	TP53 MIR34A MIR17
12	negative regulation of hydrogen peroxide-mediated programmed cell death	GO:1901299	9.69	MET MIR21
13	miRNA-mediated gene silencing by inhibition of translation	GO:0035278	9.67	MIR17 MIR200B MIR21 MIR221
14	negative regulation of vascular wound healing	GO:0061044	9.57	MIR34A MIR200B
15	negative regulation of vascular associated smooth muscle cell apoptotic process	GO:1905460	9.56	MIR21 MIR17
16	positive regulation of metalloendopeptidase activity	GO:1904685	9.54	MIR21 MIR17
17	negative regulation of interleukin-21 production	GO:0032705	9.48	MIR221 MIR21
18	negative regulation of sprouting angiogenesis	GO:1903671	9.46	MIR17 MIR18A MIR221 MIR34A
19	negative regulation of gene expression	GO:0010629	9.44	TP53 TERT PIK3CA MIR34A MIR21 MIR200B

Molecular functions related to Hepatocellular Carcinoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	mRNA 3'-UTR binding	GO:0003730	9.56	TP53 MIR34A MIR224 MIR21 MIR200B MIR17
2	mRNA base-pairing translational repressor activity	GO:1903231	9.23	MIR34A MIR224 MIR221 MIR21 MIR200B MIR18A